Medicus Pharma Receives FDA “Study May Proceed” Letter For NDA-Enabling Registrational Skinject® Study In Patients With Gorlin Syndrome
MDCX•FDA clears registrational Skinject study to proceed
July 27 (Reuters) - Medicus Pharma Ltd MDCX.O:
- Medicus Pharma receives FDA “Study May Proceed” letter for NDA-enabling registrational Skinject® study in patients with Gorlin syndrome
Source text: ID:nGNX5HvJV4
Further company coverage: MDCX.O
